InflaRx Doses First Patient in INF904 Phase 2a Study
Ticker: IFRX · Form: 6-K · Filed: Dec 20, 2024 · CIK: 1708688
Sentiment: neutral
Topics: clinical-trial, drug-development, phase-2a
TL;DR
InflaRx dosed first patient in INF904 Phase 2a study for CSU and HS.
AI Summary
On December 20, 2024, InflaRx N.V. announced that the first patient has been dosed in its Phase 2a basket study for its oral C5aR inhibitor, INF904. This multi-center, open-label study will investigate INF904 in patients with chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS).
Why It Matters
This marks a significant step in the development of INF904, a potential new treatment for autoimmune and inflammatory conditions like CSU and HS.
Risk Assessment
Risk Level: medium — Clinical trial progress is inherently risky, with potential for delays, unexpected results, or regulatory hurdles.
Key Players & Entities
- InflaRx N.V. (company) — Registrant and developer of INF904
- INF904 (drug) — Oral C5aR inhibitor being studied
- December 20, 2024 (date) — Date of the announcement and dosing
- chronic spontaneous urticaria (CSU) (condition) — One of the target indications for INF904
- hidradenitis suppurativa (HS) (condition) — Another target indication for INF904
FAQ
What is the primary goal of the Phase 2a basket study for INF904?
The study aims to investigate the efficacy and safety of InflaRx's oral C5aR inhibitor, INF904, in patients with chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS).
What type of study is the Phase 2a trial for INF904?
It is a multi-center, open-label study.
What is INF904?
INF904 is an oral C5aR inhibitor developed by InflaRx N.V.
When was the first patient dosed in the study?
The first patient was dosed on December 20, 2024.
What are the specific conditions being investigated in this Phase 2a study?
The study is investigating INF904 in patients with chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS).
Filing Stats: 652 words · 3 min read · ~2 pages · Grade level 12.3 · Accepted 2024-12-20 08:01:01
Filing Documents
- ef20040227_6k.htm (6-K) — 12KB
- ef20040227_ex99-1.htm (EX-99.1) — 13KB
- image00003.jpg (GRAPHIC) — 3KB
- 0001140361-24-050007.txt ( ) — 31KB
FORWARD-LOOKING STATEMENTS
FORWARD-LOOKING STATEMENTS This Report contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential" or "continue," among others. Forward-looking statements appear in a number of places throughout this Report and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading "Risk Factors" and "Cautionary statement regarding forward looking results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law. EXHIBIT INDEX Exhibit No. Description 99.1 Press Release, dated December 20, 2024
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INFLARX N.V. Date: December 20, 2024 By: /s/ Niels Riedemann Name: Niels Riedemann Title: Chief Executive Officer